ALK and non-small cell lung carcinoma: The efficacy of nivolumab was found to be inferior to that of docetaxel in patients with EGFR mutations in the Checkmate 057 trial [27], but there is less data on the efficacies of ICIs for NSCLC with ALK rearrangement.